Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for You?

By ZynoxRX Editorial Team · June 27, 2026

Semaglutide and tirzepatide are the two most prescribed GLP-1 medications for weight management, and while they are often discussed interchangeably, they are meaningfully different drugs.

How they work

Semaglutide is a GLP-1 receptor agonist: it mimics the hormone glucagon-like peptide-1, which slows gastric emptying, reduces appetite signaling in the brain, and improves insulin response. Tirzepatide adds a second mechanism — it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, which appears to amplify both the metabolic and appetite effects.

What the trials show

In the STEP 1 trial, participants on weekly semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, versus 2.4% with placebo. In SURMOUNT-1, participants on the highest tirzepatide dose lost an average of 20.9% over 72 weeks. Head-to-head, tirzepatide has shown greater average weight loss — but individual response varies widely, and more medication is not automatically better medication.

How physicians choose

Prescribers weigh your health history, side-effect tolerance, budget, and goals. Semaglutide has a longer real-world track record; tirzepatide may suit patients who plateau on GLP-1-only therapy. Both require gradual dose titration and ongoing clinical supervision.

This article is for education only and is not medical advice. Only a licensed physician can determine whether GLP-1 therapy is appropriate for you.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded GLP-1 medications are not FDA-approved as finished products. Consult a licensed physician before starting any weight management medication. Individual results may vary. No outcomes are guaranteed.